Extreme Dissapointement in Botched LaunchFollowed the Aristotle 'launch' and financials.
Aristotle: It is not really a proper launch as expected.
Expected was a launch through a capable 3rd party paying the bills
and getting all the clients (patients) for the tests.
Now what happened?
They buy a clinic for roughly 1/3 of MCAP (3/4 left),
trying to use it for a 'self launch'.
This is like when you are a failed author of your new book
nobody likes to publish and you decide to pay for the press
and distribution yourself. Probably not a very successful launch.
This not enough, financials only add up in more and more costs.
Covid testing wasn't able to produce positive results as they burn
everything through *who knows what* (they call it R&D and management).
Now what do you expect will happen to cash flow,
with the new clinic for 1/3 of mcap?
Only purchased to push Aristotle into the public:
clinic acquisition costs $15M+
clinic annual burn rate of ??? (I guess around $5M?)
Company has failed big time and even left analysts speechless
with their 'self launching'.
Company could hardly keep up with the current running costs
without this clinic and only thanks to constant stock offerings.
Last but not least: Aristotle would need proper US FDA
blessing (certification), as only that would lead to proper
reimbursements from insurers.
Same FDA certificate would also allow to roll out Aristotle
to the best and most efficient labs across the US, EU and so forth.
These lab rights they are using won't help them at all,
as it also didn't help them with the other tests.
BTW, some (of not most) of the cancer tests only show sensitivity < 90.
Even the once crooked biotech companies like PolarityTE are now walking
this FDA path (yes no test, but transplant).
Also this animal/human testing company is going the FDA route: VolitionRx.
StageZero's strategy has failed at this point.
Would have been better to invest the 15M shares in an FDA approved
Aristotle test.
They only showed one (old) conference paper: That won't cut it!
The moment I read the NR with the clinic acquisition, I sold.
Best of luck to you.
PS: Yes, I am an old genenews trader and got out alive.
Hope 200dma will hold.
In case they followup with a new offering to cover the new clinic costs
for the next 12 month, I would eye for 50c.